Roger Dumoulin-White, President & CEO of Theralase Technologies (TLTFF:OTC, TLT:TSX.V) explains the company’s two divisions, the therapeutic laser division and the anticancer division.
Theralase is a medical device company we have two different divisions. We have a therapeutic laser division, which is an operating division, where we manufacture therapeutic lasers to heal pain, eliminate inflammation, accelerate tissue healing.
We have a TLC 1000 product where we have 800 locations in Canada and 400 location in the U.S. and internationally. Addressable market is about 100 Billion in the US. Revenues for 2015 were $2 million. We’re tracking $5 million in 2016.
We recently had approved our next generation product, the TLC 2000, which we are starting to roll out in Canada and the United States as we speak.
Second division is anticancer division where we’ve in-licensed photodynamic compounds which have an affinity for cancer cells and then once they enter the cancer cells and we light activate them, destroy the cancer cells without affecting healthy tissue. It’s a beautiful one two punch to destroy the primary tumor and also to prevent the recurrence.
It has been approved for clinical trial, phase 1B clinical trial, with Princess Margaret Cancer Center, and we are just waiting our final approval, which is called an ITA for approval of the laser, which we should have later this year.
We feel that we’re going to be successful on our phase 1B, move to our phase two clinical trial and making it a pivotal trial meaning that we can go to commercialization thereafter.